Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 1/2 2Phase 3 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Lymphoma, B-Cell 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Interventional × abivertinib × Clear all
NCT02448251 2019-10-29

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer

ACEA Therapeutics, Inc.

Phase 1 Terminated
28 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03053219 2019-02-01

Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Phase 1 Completed
7 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03060850 2019-02-01

A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Phase 1 Unknown
184 enrolled
Lymphoid

Lymphoma, B-Cell

NCT03001609 2017-10-03

Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Phase 1 Completed
7 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡